Indo Us Bio-Tech Limited share price
Indo Us Bio-Tech Limited engages in the production, processing, packing, and marketing of seeds in India. The company offers vegetable seeds, such as tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, pepper, chilly, sweet pepper, beet root, cow pea, corriander, onion, watermelon, musk melon, and flower seeds; cotton seeds; and oil seeds, including castor, groundnut, sesamum, mustard, and soyabean seeds. It also provides cumin and isabgul spices seeds; pulses seeds comprising val, gram, black gram, and green gram seeds; and cereals seeds consisting of wheat, maize, bajra, and pegeon pea seeds. It also exports its pr…Read more
- Market Cap₹ 144 Cr.
- Current Price₹ 71.95
- High / Low₹ 159 / 70
- Stock P/E12.6
- Book Value₹ 46
- Dividend Yield0.00 %
- ROCE17.2 %
- ROE15.30 %
- Face Value₹ 10.0
More figures (10)
- EPS (TTM)₹ 5.70
- Price / Book1.56
- OPM14.7 %
- Debt / Equity0.40
- Sales growth (4Y)21.4 %
- Profit growth (4Y)21.9 %
- Promoter holding75.5 %
- EV / EBITDA11.3
- Beta0.27
- All-time high₹ 388
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| INDOUS | -6.75% | -16.04% | -34.54% | -40.81% | -42.54% | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Indo Us Bio-Tech Limited is in the Agricultural Inputs industry (Basic Materials), with a market value of ₹144 crore.
- It trades at 12.6 times its last 12 months' earnings and 1.6 times book value.
- Revenue grew 21.4% a year over the last 4 years, profit 21.9% a year.
- Return on equity was 15.3% and return on capital employed 17.2% in the latest year.
- Debt was 0.40 times shareholders' equity.
- The share price is 54.8% below its 52-week high and down 42.5% over one year.
- Promoters and insiders hold about 75.5%; institutions about 0.0%.
Pros
AI- Healthy return on equity of 17.5% on average over the last 3 years.
- Promoters hold a large stake of 68.29%.
Cons
AI- Latest quarter (Jun 2026): profit fell 35% from a year ago.
- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Indo Us Bio-Tech Limited
Indo Us Bio-Tech Limited engages in the production, processing, packing, and marketing of seeds in India. The company offers vegetable seeds, such as tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, pepper, chilly, sweet pepper, beet root, cow pea, corriander, onion, watermelon, musk melon, and flower seeds; cotton seeds; and oil seeds, including castor, groundnut, sesamum, mustard, and soyabean seeds. It also provides cumin and isabgul spices seeds; pulses seeds comprising val, gram, black gram, and green gram seeds; and cereals seeds consisting of wheat, maize, bajra, and pegeon pea seeds. It also exports its products. The company was incorporated in 2004 and is based in Ahmedabad, India.
- Head office
- Ahmedabad
Peer comparison
Basic MaterialsAgricultural Inputs
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Indo Us Bio-Tech | 71.95 | 12.6 | 144 | 0.00 | 3 | -35.41 | 33 | 7.21 | 17.2 | 15.3 | 1.56 | 14.7 | 0.40 | 75.49 | 110 | 21.4 |
| 2. | Coromandel International | 1,758.60 | 28.3 | 51,798 | 0.62 | 381 | -34.30 | 8,165 | 63.68 | 20.9 | 16.5 | 4.12 | 14.2 | 0.52 | 59.56 | 20,223 | 10.2 |
| 3. | The Fertilisers and Chemicals Travancore | 733.20 | — | 47,443 | 0.00 | -68 | -948.75 | 1,568 | 65.14 | 14.2 | -2.9 | 34.32 | 1.2 | 2.95 | 0.00 | 4,051 | 0.0 |
| 4. | UPL | 534.65 | 21.5 | 45,193 | 1.11 | 10 | -98.88 | 10,181 | -34.62 | 9.9 | 5.7 | 1.30 | 13.8 | 0.68 | 33.73 | 51,303 | -1.2 |
| 5. | PI Industries | 2,190.00 | 28.5 | 33,224 | 0.68 | 244 | -38.95 | 1,702 | -10.43 | 14.7 | 12.4 | 2.96 | 20.4 | 0.03 | 46.20 | 6,714 | 1.1 |
| 6. | Sumitomo Chemical India | 404.75 | 34.9 | 20,203 | 0.32 | 215 | 115.73 | 1,063 | 56.51 | 21.0 | 17.3 | 5.96 | 20.5 | 0.02 | 75.46 | 3,209 | -2.6 |
| 7. | Chambal Fertilisers and Chemicals | 388.10 | 8.1 | 15,549 | 3.07 | 524 | 301.66 | 5,027 | 105.29 | 21.8 | 20.4 | 1.49 | 11.4 | 0.10 | 63.29 | 20,793 | -9.2 |
| 8. | Paradeep Phosphates | 147.16 | 14.3 | 15,283 | 1.02 | 393 | 127.97 | 6,124 | 46.03 | 20.7 | 15.7 | 2.25 | 18.2 | 1.02 | 58.43 | 10,191 | 28.8 |
| 9. | E.I.D.- Parry (India) | 694.15 | 26.7 | 12,353 | 0.00 | 142 | -42.50 | 9,018 | 3.41 | 15.7 | 6.8 | 1.40 | 10.0 | 0.98 | 46.92 | 27,240 | 9.6 |
| 10. | Madhya Bharat Agro Products | 167.10 | 47.3 | 7,321 | 0.06 | 33 | 16.86 | 416 | 1.61 | 19.4 | 31.5 | 13.32 | 16.6 | 1.56 | 0.00 | 1,867 | 33.0 |
| Median: 25 Co. | 469.70 | 14.3 | 5,781 | 0.60 | 178 | -34.86 | 3,365 | 26.62 | 18.3 | 12.4 | 1.49 | 11.6 | 0.60 | 52.68 | 8,452 | 3.5 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Standalone figures in ₹ crore
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Standalone figures in ₹ crore
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own past sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
No separate related-party filing among the recent announcements of the company.
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| 104 | 110 | 143 | |
| YOY Sales Growth % | 6.36% | ||
| 85 | 93 | 122 | |
| Material Cost % | 70% | 73% | 74% |
| Employee Cost % | 1% | 1% | 1% |
| Other Expenses % | 11% | 11% | 10% |
| Operating Profit | 19 | 17 | 21 |
| OPM % | 18% | 15% | 15% |
| Other Income | 0 | 0 | 0 |
| Interest | 1 | 2 | 3 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 17 | 14 | 17 |
| 2% | 6% | 5% | |
| Current tax | 0 | 1 | |
| Deferred tax | -0 | 0 | |
| 16 | 13 | 16 | |
| YOY Profit Growth % | -19.33% | ||
| EPS in Rs | 8.12 | 6.54 | 8.04 |
| Dividend Payout % | 3% |
Compounded Sales Growth
- TTM:
- -3%
Compounded Profit Growth
- TTM:
- -17%
Stock Price CAGR
- 1 Year:
- -43%
Return on Equity
- 4 Years:
- 16%
- Last Year:
- 15%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 20 | 20 | 20 |
| Reserves | 44 | 43 | 58 | 72 |
| 12 | 14 | 15 | 37 | |
| Long term borrowings | 2 | 3 | 3 | 1 |
| Short term borrowings | 10 | 12 | 12 | 36 |
| 3 | 7 | 4 | 4 | |
| Trade payables | 2 | 4 | 1 | 0 |
| Minority interest | 0 | 0 | ||
| Current liabilities | 12 | 19 | 16 | 40 |
| Total Liabilities | 69 | 84 | 98 | 133 |
| 9 | 10 | 10 | 12 | |
| Gross block | 9 | 14 | 10 | 12 |
| Accumulated depreciation | 4 | 4 | ||
| CWIP | 1 | 4 | 1 | |
| 59 | 70 | 88 | 121 | |
| Inventories | 27 | 52 | 71 | 100 |
| Trade receivables | 25 | 19 | 15 | 14 |
| Cash & equivalents | 0 | 1 | 0 | 6 |
| Current assets | 60 | 73 | 87 | 121 |
| Total Assets | 69 | 84 | 98 | 133 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1 | 2 | 1 | -13 | |
| Profit for the year | 7 | 8 | 16 | 13 |
| Working capital changes | -9 | -9 | -18 | -30 |
| Direct taxes paid | -0 | -0 | -0 | -0 |
| -7 | -3 | -1 | -2 | |
| Fixed assets purchased | -2 | -3 | -1 | -2 |
| Fixed assets sold | 0 | |||
| Investments sold | 0 | 1 | ||
| 6 | 1 | -1 | 20 | |
| Proceeds from borrowings | 1 | 3 | 1 | 24 |
| Repayment of borrowings | -2 | -2 | ||
| Interest paid | -1 | -2 | -1 | -2 |
| Dividends paid | -1 | |||
| Net Cash Flow | 0 | 1 | -1 | 6 |
| Free Cash Flow | -1 | -0 | 1 | -15 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 13.3% | 14.1% | 23.0% | 15.3% |
| ROCE | — | 14.9% | 15.6% | 22.0% | 17.2% |
| Operating margin | — | 13.9% | 14.2% | 17.3% | 14.7% |
| Net margin | — | 11.7% | 11.3% | 15.7% | 11.9% |
| Debt / equity | — | 0.21 | 0.23 | 0.19 | 0.40 |
| Current ratio | — | 4.87 | 3.87 | 5.31 | 3.05 |
| Debtor days | — | 146 | 95 | 53 | 45 |
| Inventory days | — | 215 | 362 | 347 | 444 |
| Days payable | — | 14 | 31 | 5 | 2 |
| Cash conversion cycle | — | 347 | 426 | 395 | 487 |
| Working capital days | — | 281 | 272 | 247 | 268 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 68.29%
- FIIs 0.01%
- DIIs 0.25%
- Public 31.45%
| % | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoters | 70.17% | 70.17% | 70.17% | 70.17% | 70.17% | 70.17% | 68.29% | 68.29% | 68.29% |
| 0.18% | 0.01% | 0.01% | |||||||
| Foreign portfolio investors (Cat. I) | 0.18% | 0.01% | 0.01% | ||||||
| DIIs | 0.25% | ||||||||
| 29.83% | 29.82% | 29.83% | 29.83% | 29.83% | 29.83% | 31.53% | 31.70% | 31.45% | |
| Retail (up to ₹2 lakh) | 5.84% | 6.06% | 6.53% | 6.75% | 7.13% | 7.92% | 8.74% | 8.85% | 8.38% |
| HNIs (above ₹2 lakh) | 17.96% | 18.15% | 17.81% | 17.61% | 17.01% | 15.77% | 15.72% | 15.66% | 16.10% |
| NRIs | 0.14% | 0.16% | 0.16% | 0.16% | 0.17% | 0.18% | 0.17% | 0.16% | 0.15% |
| Bodies corporate | 3.76% | 3.78% | 3.62% | 3.60% | 3.79% | 4.22% | 5.03% | 5.19% | 5.10% |
| No. of Shareholders | 971 | 2,828 | 2,780 | 3,112 | 4,130 | 4,738 | 4,531 | 4,690 | 4,629 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Documents
Announcements
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Indo Us Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201814-Oct-2026
- Shareholders meetingIndo Us Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange r…02-Oct-2026
- Shareholders meetingIndo Us Biotech Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 202630-Sep-2026
- Trading WindowIndo Us Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- Copy of Newspaper PublicationIndo Us Biotech Limited has informed the Exchange about Copy of Newspaper Publication06-Sep-2026
- Shareholders meetingIndo Us Biotech Limited has informed the Exchange regarding Intimation of Book Closure for the purpose of 22nd AGM pursuant to Regulation 42 of SEBI (LODR)05-Sep-2026
- Shareholders meetingIndo Us Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 202605-Sep-2026
- Outcome of Board MeetingIndo Us Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.05-Sep-2026
- Copy of Newspaper PublicationIndo Us Biotech Limited has informed the Exchange about Copy of Newspaper Publication relating to unaudited quarterly Financial Results for the quarter ended on 30th June, 202613-Aug-2026
- Integrated Filing- FinancialSubmission of Standalone Unaudited Financial Results of the Company for the quarter ended June 30, 2026.12-Aug-2026
- Outcome of Board MeetingIndo Us Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.12-Aug-2026
- Shareholders meetingIndo Us Biotech Limited has informed the Exchange regarding Proceedings of Postal Ballot05-Aug-2026
Annual reports
Credit ratings
None filed recently.
Concalls & investor meets
None filed recently.
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 3 Dec 2024
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Indo Us Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 14-Oct-2026
- Shareholders meetingIndo Us Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange r…NSE filing · 02-Oct-2026
- Shareholders meetingIndo Us Biotech Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026NSE filing · 30-Sep-2026
- Trading WindowIndo Us Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 28-Sep-2026
- Copy of Newspaper PublicationIndo Us Biotech Limited has informed the Exchange about Copy of Newspaper PublicationNSE filing · 06-Sep-2026
- Shareholders meetingIndo Us Biotech Limited has informed the Exchange regarding Intimation of Book Closure for the purpose of 22nd AGM pursuant to Regulation 42 of SEBI (LODR)NSE filing · 05-Sep-2026
- Shareholders meetingIndo Us Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026NSE filing · 05-Sep-2026
- Outcome of Board MeetingIndo Us Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.NSE filing · 05-Sep-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Indo Us Bio-Tech Limited
What is the share price of Indo Us Bio-Tech Limited today?
What is the market cap of Indo Us Bio-Tech Limited?
What is the P/E ratio of Indo Us Bio-Tech Limited?
Is Indo Us Bio-Tech Limited a good investment?
How can I buy Indo Us Bio-Tech Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.